 Psoriasis
"Psoriasis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
| Descriptor ID |
D011565
|
| MeSH Number(s) |
C17.800.859.675
|
| Concept/Terms |
Pustulosis of Palms and Soles- Pustulosis of Palms and Soles
- Pustulosis Palmaris et Plantaris
- Palmoplantaris Pustulosis
- Pustular Psoriasis of Palms and Soles
|
Below are MeSH descriptors whose meaning is more general than "Psoriasis".
Below are MeSH descriptors whose meaning is more specific than "Psoriasis".
This graph shows the total number of publications written about "Psoriasis" by people in this website by year, and whether "Psoriasis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 1997 | 1 | 0 | 1 | | 1998 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2001 | 0 | 1 | 1 | | 2002 | 3 | 1 | 4 | | 2003 | 2 | 0 | 2 | | 2004 | 2 | 1 | 3 | | 2005 | 1 | 2 | 3 | | 2006 | 0 | 3 | 3 | | 2008 | 1 | 0 | 1 | | 2009 | 5 | 1 | 6 | | 2010 | 0 | 1 | 1 | | 2011 | 3 | 0 | 3 | | 2012 | 3 | 0 | 3 | | 2013 | 2 | 2 | 4 | | 2015 | 5 | 1 | 6 | | 2016 | 5 | 1 | 6 | | 2017 | 5 | 1 | 6 | | 2018 | 9 | 0 | 9 | | 2019 | 3 | 1 | 4 | | 2020 | 3 | 0 | 3 | | 2021 | 6 | 2 | 8 | | 2022 | 1 | 0 | 1 | | 2023 | 5 | 0 | 5 | | 2024 | 3 | 2 | 5 | | 2025 | 5 | 1 | 6 | | 2026 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Psoriasis" by people in Profiles.
-
Quan NG, Garcia-Creighton E, Thapar M, Kille B, Tucker J, Schmiege SJ, Boos MD, Fernández Faith E, Paller AS, Siegel DH, Siegel LH, Varki RT, Yan AC, Kohn LL. Pediatric Skin Disease Frequencies and Dermatology Use by Race and Ethnicity in US Children's Hospitals. JAMA Dermatol. 2026 Jun 01; 162(6):599-606.
-
Stein Gold L, Gottlieb AB, Armstrong AW, Alkousakis T, Bissonnette R, Langley RG, Krueger J, Papp K, Choi O, Rowland K, Chan D, Jeyarajah J, Park-Wyllie L, Gao LL, Gordon KB, Merola JF, Lebwohl MG, Strober B. SPECTREM phase IIIb clinical trial results through week 16: guselkumab efficacy and safety for the treatment of low body surface area, moderate psoriasis with high-impact site involvement. Br J Dermatol. 2026 01 06; 194(1):25-36.
-
McMichael A, Shahriari M, Stein Gold L, Alkousakis T, Choi O, Bhutani T, Rodriguez AO, Tyring SK, Chan D, Rowland K, Albrecht L, Lynde C, Yadav G, Yeung J, Park-Wyllie L, Ma T, Jeyarajah J, Gao LL, Smith S, Moore AY, Vashi N, Kindred C, Grimes P, Desai SR, Taylor SC, Alexis A. Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial. JAMA Dermatol. 2025 Sep 01; 161(9):912-922.
-
Alexis A, McMichael A, Soung J, Choi O, Alkousakis T, Alonso-Llamazares J, Shahriari M, Rodriguez AO, Bhutani T, Chan D, Rowland K, Sauder M, Hong HC, Yadav G, Yeung J, Jeyarajah J, Ma T, Gao LL, Park-Wyllie L, Green L, Lee M, Vashi N, Kindred C, Grimes P, Taylor SC, Desai SR. Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones: Cohort A of the VISIBLE Randomized Clinical Trial. JAMA Dermatol. 2025 Sep 01; 161(9):901-911.
-
Shahin MM, Gorell ES, Iqneibi M, Sun Q, Brunner HI, Hellmann J, Marathe KS. Characterization of TNF-Alpha Inhibitor Induced Paradoxical Psoriasiform Dermatitis at a Single Center via Retrospective Chart Review. Pediatr Dermatol. 2026 Jan-Feb; 43(1):84-87.
-
Alexis A, McMichael A, Vashi N, Bhutani T, Rodriguez AO, Yeung J, Choi O, Chan D, Alkousakis T, Bronner DN, Park-Wyllie L, Gao LL, Grimes P, Shahriari M, Yadav G, Kindred C, Taylor SC, Desai SR. Improving Diversity in a Novel Psoriasis Study: VISIBLE as a Framework for Clinical Trial Quality Improvement. JAMA Dermatol. 2025 Mar 01; 161(3):256-264.
-
Kantheti U, Forward TS, Lucas ED, Schafer JB, Tamburini PJ, Burchill MA, Tamburini BAJ. PD-L1-CD80 interactions are required for intracellular signaling necessary for dendritic cell migration. Sci Adv. 2025 Jan 31; 11(5):eadt3044.
-
Kumar R, Seth S, Bhargav A, Saini N, Ramachandran S. Computational identification of perturbed pathways in type 2 diabetes mellitus patients reveals necroptosis and NF-?B pathways with potential for susceptibility to psoriasis. J Biosci. 2025; 50.
-
Rafael Correia Rocha I, Finch MR, Ball JB, Harland ME, Clements M, Green-Fulgham S, Song G, Liu Y, Banov D, Watkins LR. An initial investigation of transcutaneous delivery of plasmid DNA encoding interleukin-10 for the treatment of psoriatic skin conditions. Brain Behav Immun. 2025 Jan; 123:903-913.
-
Day M, Heapy C, Norman P, Emerson LM, Murphy R, Hughes O, Thompson AR. Impact of childhood psoriasis on children and parents during transition to adolescence: An interpretative phenomenological analysis. Br J Health Psychol. 2025 Feb; 30(1):e12763.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|